Pharming (PHAR) Return on Sales (2020 - 2026)

Pharming's Return on Sales history runs 7 years deep, the most recent figure standing at 0.0% for Q1 2026.

• Quarterly Return on Sales fell 39194.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Sales was 0.0% for Q1 2026 at Pharming, down from 968.08% in the prior quarter.
• Across five years, Return on Sales topped out at 968.08% in Q4 2025 and bottomed at 1659.61% in Q4 2023.
• A 5-year average of 45.49% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2023 — Return on Sales sank 165961 bps — and 2024, when it soared 140811 bps.
• Pharming's Return on Sales stood at 0.0% in 2022, then plunged by 66121602 bps to 1659.61% in 2023, then jumped by 85 bps to 251.49% in 2024, then jumped by 485 bps to 968.08% in 2025, then slumped by 100 bps to 0.0% in 2026.
• Business Quant data shows PHAR's Return on Sales at 0.0% in Q1 2026, 968.08% in Q4 2025, and 0.0% in Q3 2025.